Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Electronic Pipette

July 13, 2010 6:50 am | Product Releases | Comments

The Eppendorf Xplorer pipette offers better pipetting with simplicity, precision, and reproducibility. With the Xplorer you get precisely adjustable parameters, maximum reproducible results, and fatigue-free work.

TOPICS:

Lentiviral MicroRNAs

July 13, 2010 6:42 am | Product Releases | Comments

Thermo Scientific has just launched miRIDIAN shMIMIC Lentiviral microRNAs, which incorporate innovative design strategies that allow consistent processing of the mature microRNA and enhanced specificity, making them ideal for a variety of microRNA research applications.

TOPICS:

GemVax Releases Encouraging Data From TeloVac Study

July 13, 2010 6:23 am | News | Comments

KAEL-GemVax, a leading oncology vaccine company, has announced, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer.

TOPICS:
Advertisement

New Mice Better Model Drug-Resistant Depression

July 13, 2010 6:13 am | News | Comments

New research shows that a unique strain of laboratory mice characterized at Penn State University has behavioral, hormonal, and neurochemical characteristics that are similar to those of human patients with drug-resistant forms of depression.

TOPICS:

New Technique Speeds Decoding of Epstein-Barr Virus

July 13, 2010 6:09 am | News | Comments

SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.

TOPICS:

IOM Reports to FDA on Post-Market Safety Trials

July 13, 2010 5:54 am | News | Comments

Amid growing concerns about clinical trials for drugs that have been approved by the FDA but are later linked to serious health risks, an independent committee at the Institute of Medicine has developed a conceptual framework to guide the agency through the tough decision of ordering such controversial "post-market" drug-safety trials.

TOPICS:

Covidien Buys ev3 for $2.6B

July 13, 2010 5:45 am | News | Comments

Drug and medical device maker Covidien said it has closed its $2.6 billion acquisition of endovascular surgery device maker ev3 Inc.

TOPICS:

Avandia Problems Worsen Ahead of Safety Review

July 13, 2010 5:36 am | by Matthew Perrone | News | Comments

An exhaustive 700-page review by federal health scientists reinforces potential ties between the diabetes pill Avandia and heart attack and death, opening the door for government action, including a possible withdrawal of the once blockbuster drug.

TOPICS:
Advertisement

Obama Announces New Strategy in AIDS Fight

July 13, 2010 5:31 am | by Julie Pace | News | Comments

President Barack Obama is announcing a new national strategy for combatting HIV and AIDS, aimed at stopping new infections and increasing access to care for people living with the virus.

TOPICS:

Qnexa Facing Uphill Battle Over Safety

July 13, 2010 5:26 am | News | Comments

Vivus Inc.'s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week.

TOPICS:

Celsis Suing Over ADME Assay

July 13, 2010 5:09 am | News | Comments

Celsis In Vitro, Inc. announced that it has filed a patent infringement lawsuit against Invitrogen Corporation and CellzDirect, Inc. in United States District Court and has moved for a preliminary injunction.

TOPICS:

Making Biologic Drugs More Affordable

July 12, 2010 12:22 pm | by Guy-Charles Fanneau de La Horie, Chief Executive Officer, Neovacs S.A., Paris, France | Articles | Comments

Biologics, and in particular monoclonal antibodies, are the fastest growing segment of the branded prescription drug market, and the pharmaceutical industry is investing heavily in the field.

TOPICS:

BMS Preemptively Recalling Coumadin

July 12, 2010 9:58 am | News | Comments

Bristol-Myers Squibb Co. said it is recalling eight production lots of its anti-clotting drug Coumadin because the amount of the active ingredient in the drug could change.

TOPICS:

Kinase Assay

July 12, 2010 8:24 am | Drug Discovery & Development | Product Releases | Comments

Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a flexible and complete kinase solution for the profiling of lead compounds against kinases representative of all major families of the kinome.

TOPICS:

Controlled-Release Polymers

July 12, 2010 8:17 am | Drug Discovery & Development | Product Releases | Comments

Dow Wolff Cellulosics announced the launch of METHOCEL Direct Compression (DC) Premium Grade Hypromellose Polymers, which can reduce the costs of manufacturing matrix tablets by eliminating the wet granulation process.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading